Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and Pim-3-silencing effects

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1503-1513

  Guo, Qie ^a,b   Lan, Peixiang ^a   Yu, Xin ^a   Han, Qiuju ^a   Zhang, Jian ^a   Tian, Zhigang ^a,c   Zhang, Cai ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEIN DERIVATIVE; PROTEIN KINASE PIM 3; SHORT HAIRPIN RNA; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; ONCOPROTEIN; PIM3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENE VECTOR; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LIVER CELL CARCINOMA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING;

EID: 84902659434     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0722     Document Type: Article

References (45)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
2. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-Like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006;66:7-14.
3. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004-15.
4. Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci 2011;102:1437-42.
5. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Badmediate apoptosis in human pancreatic cancer cell lines activity. Cancer Res 2006;66:6741-7. (Pubitemid 44085632)
6. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007;98:321-8. (Pubitemid 46195601)
7. Fujii C, Nakamoto Y, Lu P. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005;114:209-18. (Pubitemid 40194286)
8. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and in.ammation: independent or interdependent processes? Curr Opin Immunol 2007;19:203-8. (Pubitemid 46356963)
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
10. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011;60:319-26.
11. Fu YX. New immune therapy targets tumor-associated environment: from bone marrow to tumor site. Cell Mol Immunol 2012;9:1-2.
12. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-84.
13. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol Cell Biol 2007;85:446-57. (Pubitemid 47367509)
14. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9. (Pubitemid 38314424)
15. Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012;9:434-8.
16. Alter G, Suscovich TJ, Teigen N, Meier A, Streeck H, Brander C, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007;178:7658-66. (Pubitemid 46898036)
17. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13:859-75.
18. Li Z, Zhang C, Zhou Z, Zhang J, Zhang J, Tian Z. Small intestinal intraepithelial lymphocytes expressing CD8 and T cell receptor γδ are involved in bacterial clearance during Salmonella enterica serovar Typhimurium infection. Infect Immun 2012;80:565-74.
19. Lan P, Zhang C, Han Q, Zhang J, Tian Z. Therapeutic recovery of HBV-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 2013;58:73-85.
20. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
21. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9. (Pubitemid 41464506)
22. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-31. (Pubitemid 46870309)
23. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-67. (Pubitemid 37432672)
24. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-9. (Pubitemid 38992921)
25. + CD25hi T regulatory cells. Eur J Immunol 2005;35:2452-8.
26. + T cells are required for NK cell activation in vivo upon Leishmania major infection. J Immunol 2010;185:2174-81.
27. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innateantiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31. (Pubitemid 38314425)
28. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012;72:2473-80.
29. Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, et al. The Pim kinases: new targets for drug development. Curr Drug Targets 2011;12:2059-66.
30. Wu Y, Wang YY, Nakamoto Y, Li YY, Baba T, Kaneko S, et al. Accelerated hepatocellular carcinoma development in mice expressing expressing the Pim-3 transgene selectively in the liver. Oncogene 2010; 29:2228-37.
31. Aho TL, Lund RJ, Ylikoski EK, Matikainen S, Lahesmaa R, Koskinen PJ. Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation. Immunology 2005;116:82-8. (Pubitemid 41208355)
32. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-91. (Pubitemid 29128500)
33. Li YY, Wu Y, Tsuneyama K, Baba T, Mukaida N. Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells. Cancer Sci 2009;100:396-404.
34. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol 2009;183:6078-86.
35. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol 2010;184:939-46.
36. Lin KJ, Lin TM, Wang CH, Liu HC, Lin YL, Eng HL. Down-regulation of Toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma. Hum Pathol 2013;44:534-41.
37. Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 2010;51:35-42.
38. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2012;90:187-96.
39. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011;34:1-15.
40. Berger M, Ablasser A, Kim S, Bekeredjian-Ding I, Giese T, Endres S, et al. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J Immunother 2009;32:262-71.
41. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8- mediated activation of human NK cells results in accessory celldependent IFN-γ production. J Immunol 2005;175:1636-42. (Pubitemid 41023066)
42. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109:5346-54. (Pubitemid 46890556)
43. Li Z, Pradera F, Kammertoens T, Li B, Liu S, Qin Z. Cross-talk between T cells and innate immune cells is crucial for IFN-γ-dependent tumor rejection. J Immunol 2007;179:1568-76.
44. Tsukada K, Kitazawa T, Fukushima A, Okugawa S, Yanagimoto S, Tatsuno K, et al. Macrophage tolerance induced by stimulation with Toll-like receptor 7/8 ligands. Immunol Lett 2007;111:51-6. (Pubitemid 47017477)
45. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 2011;71:5123-33.